Skip to main content
OpenTrials
Completed

NCT Number: NCT07319689

Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients

This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Predictor Autoimmune Diseases Autoimmune Diseases of the Nervous System Immune System Diseases Myasthenia Gravis Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Neurodegenerative Diseases Neuromuscular Diseases Neuromuscular Junction Diseases Non-Thymomatous Paraneoplastic Syndromes Paraneoplastic Syndromes, Nervous System Thoracoscopic Thymectomy Thymomatous

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction.

Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes.

Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both sexes.
  • Confirmed diagnosis of Myasthenia Gravis (MG).
  • Underwent Thoracoscopic thymectomy.
  • Availability of complete preoperative and postoperative records, including imaging and histopathology.
  • Minimum follow-up of 9 months post-surgery.

Exclusion criteria

  • Patients who underwent thymectomy for indications other than MG.
  • Incomplete medical records or loss to follow-up before outcome assessment.
  • Patients with concomitant neuromuscular disorders other than MG

Treatment and study plan

Data Collection

Other

Data were obtained from patient files, operative notes, and electronic medical records.

Primary outcomes

  1. Proportion of patients achieving complete stable remission

    Time frame: 12 months post-procedure

    Proportion of patients achieving complete stable remission was recorded.

Secondary outcomes

  1. Proportion of patients achieving pharmacologic remission

    Time frame: 12 months post-procedure

    Proportion of patients achieving pharmacologic remission was recorded.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jan 6, 2026
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.